Fig. 3: Estimated time to independent walking curves in females with CDD, by starting age of observation.
From: Factors influencing the attainment of major motor milestones in CDKL5 deficiency disorder
Profile A: Variant group (truncating variants after aa781), mosaicism (absent), ever honeymoon period (yes), number of anti-seizure medications used in first year of life (0–3), age at seizure onset (>1.5 months), formal therapy during first year of life (yes). Profile D: Variant group (truncating variants between aa172 and aa781), mosaicism (absent), ever honeymoon period (no), number of anti-seizure medications used in first year of life (≥4), age at seizure onset (≤1.5 months), formal therapy during first year of life (no).
